Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Wisp

Claya
Graded #268

Lower grade

vs+12.200000000000003
Wisp
Graded #59

Higher grade

The verdict

Wisp takes it — 75/100 to 62.8/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +41
42
83
Dose & formulationWisp +13
75
88
Clinical oversightEven
82
82
Labs & monitoringEven
53
53
FulfillmentClaya +1
67
66
Contract termsClaya +6
61
55
Claya · left barWisp · right bar

The numbers

MetricClayaWisp
WeighScore62.8/10075/100
GradeCC
Scorecard rank#268#59
Semaglutide$299/mo (compounded)$225/mo (compounded oral)
Tirzepatide$299/mo (compounded)$99/mo (starting dose, brand-name)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Claya

Graded #268 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Wisp

Graded #59 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
  • Pharmacy partners not named
  • States served not listed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard